Biotech Bubble Valuations From Sam Islay By: Benzinga via Benzinga April 02, 2015 at 07:13 AM EDT OrbiMed Advisors managing partner Sam Isaly told CNBC that biotech could be volatile, however, the valuations were ... Read More >> Related Stocks: Molina Healthcare Inc Nasdaq Biotechnology Ishares ETF Regeneron Pharmaceuticals Ziopharm Oncology IN